CLINICAL_TRIALS
trial_result
· 2026-03-04
Clinical Trial Update: A Study of AK112 in Patients With Unresectable Hepatocellular Carcinoma (HCC) [Phase 2]
Summary
This is a completed Phase 2 clinical trial evaluating AK112 in patients with unresectable hepatocellular carcinoma.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Akeso | Conditions: Hepatocellular Carcinoma | Phase 2 | Status: COMPLETED